1698 results about "Pharmaceutical technology" patented technology

The invention provides a medical wholesale and retail comprehensive service method and system based on the Internet, and relates to the technical field of medicines.The medical wholesale and retail comprehensive service method comprises the steps that a hospital HIS system is docked in real time through an API, and electronic prescription data are collected; the collected electronic prescription data is connected with a medicine wholesale enterprise ERP system, the inventory state, batch number and validity period information of each medicine are obtained, and inventory information is obtained. According to the invention, through real-time connection of the hospital HIS system, the drug wholesale enterprise ERP system and the retail terminal POS system, inventory information can be obtained and dynamic management can be carried out. The real-time data updating not only improves the inventory turnover rate, but also can automatically warn the medicines close to the expiration date, and reduces the loss of the expired medicines. The LSTM neural network is adopted to predict the drug demand, and the replenishment suggestion is generated in combination with the linear programming model, so that the replenishment process can be optimized while the operation cost is minimized, and sufficient and efficient inventory is ensured.

The invention belongs to the technical field of medicines, and provides a cassia twig granular preparation as well as a preparation method and a product thereof. The cassia twig granule preparation is prepared from the following components in parts by weight: 35 to 50 parts of cassia twig granule extract dry paste and 50 to 105 parts of auxiliary materials, the auxiliary materials comprise lactose, beta-cyclodextrin and derivatives thereof, and citric acid. According to the invention, beta-cyclodextrin and derivatives thereof are used for replacing dextrin as an auxiliary material in the cassia twig granules, so that the interference problem of dextrin in drug detection is avoided, the formability, solubility and hygroscopicity of the cassia twig granule preparation are ensured, the stability of the preparation is improved, and the comprehensive performance is excellent.

The invention provides a preparation method of medicinal liquor and application of the medicinal liquor in preparation of analgesic and anti-inflammatory products, and relates to the technical field of medicines. The preparation method comprises the following steps: (1) crushing; (2) extracting; (3) standing and separating; and (4) freezing and filtering to obtain the medicinal liquor. In the preparation process, traditional Chinese medicine components are extracted through the steps of batch crushing, mixed extraction, standing, freezing and separation of supernate and suspension in different separation modes to obtain the medicinal liquor, and the medicinal liquor can better inhibit pain caused by thermal stimulation and chemical substances and has a better analgesic effect; the traditional Chinese medicine composition can inhibit capillary permeability increase caused by acetic acid, has a better effect of inhibiting inflammation exudation, and has remarkable analgesic and anti-inflammatory effects.

The present application belongs to the field of medical technology, and in particular, relates to an edaravone dexamethasone solution and its preparation process and application. The preparation process of the edaravone dexamethasone solution comprises the steps of: dissolving edaravone in a heated organic solvent under an inert atmosphere, cooling to no more than 30°C, adding dexamethasone to dissolve, and obtaining a mixed solution; adding water and an antioxidant to the mixed solution under an inert atmosphere for mixing treatment, adjusting the pH value of the solution to 4 to 4.5, and obtaining an edaravone dexamethasone solution. The order and conditions of adding each raw material component in the preparation process of the edaravone dexamethasone solution of the present application improve the solubility of edaravone and dexamethasone in water, solve the problem that edaravone is easily oxidized and dexamethasone is easily volatilized at room temperature, have low impurity content, good pH stability, high product quality and stability, and are conducive to the long-term preservation of the edaravone dexamethasone solution.

The utility model discloses a double-butterfly-valve sterile medicine transfer system, and relates to the technical field of pharmacy. Comprising a turnover medicine storage tank, a driving butterfly valve, a driven butterfly valve, a powder storage tank and a sterile liquid medicine storage bag, a discharging port of the turnover medicine storage tank is connected with the driving butterfly valve through a first connecting piece, and the driving butterfly valve is connected with the driven butterfly valve through a second connecting piece; the passive butterfly valve is connected with a feeding port of a powder storage tank through a third connecting piece, a first diaphragm valve is arranged at a discharging port of the powder storage tank, and the discharging port of the powder storage tank is connected with a sterile liquid medicine storage bag; by adopting the design of double butterfly valves, sterile connection is established between the turnover medicine storage tank and the powder storage tank, the reliability of hoop connection is high, the structure is simple, the operation complexity is low, the universality is high, the flexibility is high, and the cost is low.

The invention relates to an oral mucosa repairing medicine and a preparation method thereof, and belongs to the technical field of medicines, the medicine comprises barnacle peptide, salivary lactobacillus, resveratrol, a biphasic adhesion matrix, hydroxyapatite, vitamin B family and other components. The preparation method comprises the following steps: sequentially carrying out enzymolysis on barnacle gooseneck by pepsin and lumbrukinase to obtain barnacle peptide. The double-phase adhesion matrix comprises a water-phase matrix, an oil-phase matrix and lecithin; the water-phase matrix contains a chondroitin sulfate-chitosan quaternary ammonium salt compound, sodium alginate and other components; the oil-phase matrix comprises sesame oil, beeswax, a polylactic acid-glycolic acid copolymer and the like. According to the invention, barnacle peptide and salivary lactobacillus are prepared by adopting a special method and are matched with resveratrol for use, so that multi-target and multi-path promotion of oral mucosa repair can be realized; the chondroitin sulfate-chitosan quaternary ammonium salt compound is prepared through electrostatic and physical embedding, the chondroitin sulfate-chitosan quaternary ammonium salt compound is matched with other components to prepare the biphasic adhesion matrix, the biocompatibility is good, the adhesion is high, and the action time of a sustained-release drug is well prolonged.

The invention provides a mesenchymal stem cell preparation for promoting knee joint repair as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: loading transforming growth factor-beta1 and interleukin-6 on chitosan microspheres, then preparing a chitosan-oxidized starch-carboxymethyl-beta-cyclodextrin bracket loaded with sustained release microspheres, loading luteolin and quercetin, carrying out mixed culture with mesenchymal stem cells, adding a traditional Chinese medicine extract, and carrying out freeze-drying to obtain the luteolin-quercetin-modified mesenchymal stem cells. The mesenchymal stem cell preparation for promoting knee joint repair is prepared. The preparation method of the carbon anode plate for fluorine preparation is simple, the generation of polarization of the carbon anode plate is prevented, and the carbon anode plate has the advantages of low porosity, low ash content, high mechanical strength, high volume density, obviously prolonged service life, low resistivity and the like, and has a wide application prospect.

The invention discloses a preparation method and application of silymarin spray curing nano-carrier powder, and relates to the technical field of medicines and the field of foods. The method comprises the following steps: firstly, constructing a silymarin-carrier compound through a molecular self-assembly technology, and then, carrying out curing treatment on a nano-carrier by adopting a spray drying technology, so as to obtain nano-powder with good flowability. According to the preparation method disclosed by the invention, the silymarin spray curing nano-carrier powder with a core-shell structure is successfully prepared by optimizing a carrier material ratio and spray drying conditions. Experimental results show that the spray-cured nano-carrier powder prepared by the method significantly improves the solubility and stability of silymarin, and enhances the bioavailability and efficacy, so that silymarin can be more efficiently absorbed and released in a targeted manner in vivo, thereby significantly improving the therapeutic effect.

The present invention relates to the field of pharmaceutical technology, and more particularly to the use of Morinda officinalis polysaccharide in preparing a product for improving renal fibrosis. The preparation method of the Morinda officinalis polysaccharide comprises the following steps: (1) extracting Morinda officinalis from water, filtering, and obtaining a supernatant; (2) subjecting the supernatant to alcohol precipitation to obtain a precipitate; and (3) dialyzing and removing protein from the precipitate. The Morinda officinalis polysaccharide has a significant therapeutic effect in improving renal fibrosis.

The invention belongs to the technical field of medicines, and particularly discloses application of niclosamide in preparation of a medicine for treating epididymis and testis fibrosis caused by bacterial infection. A UPEG-mouse epididymis / orchitis model is firstly constructed, a result shows that a monocyte subset highly expressed by S100a4 appears in a testis, the group of cells mainly express CD11b monocyte characteristics in the early stage when entering the testis, and the group of cells are partially converted into F4 / 80 + and alpha-SMA + fibroblast characteristics in the later stage. A myeloid macrophage knockout mouse is used for constructing a UPEG-epididymis / orchitis model, and the fibrosis degree of testis and epididymis is obviously reduced; a molecular mechanism shows that S100a4 can strengthen a TGF beta-STAT3 signal channel to promote the transformation of macrophages to fibroblasts, and niclosamide can inhibit the process. Mouse in-vivo experiment results show that niclosamide can obviously inhibit UPEG-mouse epididymis and testis fibrosis.

The invention discloses a composition for treating diseases through protein degradation in a novel degradation way, and relates to the technical field of medicines. Comprising a mandolin-based androgen receptor degradation chimeric peptide (MbTACs), the mandolin-based androgen receptor degradation chimeric peptide (MbTACs) contains a targeting module YLCSSNNRERDKFRR combined with AR and a module combined with midnolin, a KLVFF sequence and a cell penetrating peptide PKKKPKV are added to the C end of the peptide, and a polypeptide molecule MbAD is formed. According to the invention, a midnolin-based MbTACs platform is developed, and the midnolin-based MbTACs platform is used for degrading specific proteins. The bifunctional molecules form a midnolin-MbTACs-target protein ternary complex between the target protein and the midnolin, and then the protein is degraded through a midnolin-proteasome way. The MbTACs can effectively degrade c-Myc and androgen antibodies in vitro and in vivo, and play an anti-tumor role. The MbTACs molecule represents a first midnolin-based target chimera, and the MbTACs molecule represents a first midnolin-based target chimera.

The present invention relates to the field of medical technology, and in particular to a semaglutide intermediate and a preparation method thereof, and a method for synthesizing semaglutide. The present invention screens different solvent combinations, finds a reaction system compatible with side chain tetrapeptide modification, main chain dipeptide modification and deprotection steps, and synthesizes semaglutide using a "one-pot method". The method does not require separation of any intermediate, does not involve complex operations such as isoelectric elution, separation, and redissolution of the intermediate, is simple to operate, has a high yield, and is conducive to industrial scale-up production. Further, the present invention uses a double Fmoc-protected dipeptide: Fmoc-His(Fmoc)-Aib-OH replaces Fmoc-His-Aib-OH·TFA as a starting material, which greatly reduces the use of Fmoc-His(Fmoc)-Aib-OH, and the feed amount is reduced from 8 to 10 times to 1 to 3 times, the atomic economy is increased, and the production cost is reduced.

The invention belongs to the technical field of medicines, and particularly relates to application of circRNA (Ribonucleic Acid) coded protein as a gastric cancer marker. The circRNA disclosed by the invention is provided with an ORF (Open Reading Frame) capable of coding a microprotein circUBE2G1-99aa of 99 amino acids, and the amino acid sequence of the protein is shown as SEQ ID NO: 1. According to the present invention, the designed circUBE2G1-99aa targeting antibody is adopted to detect the expression level of circUBE2G1-99aa in the collected clinical sample, and the expression level of circUBE2G1-99aa in the stomach cancer patient tissue is down-regulated, and is negatively correlated with the large tumor, the lymph node metastasis and the advanced pathological stage of the stomach cancer patient.

The invention belongs to the technical field of medicines, and particularly relates to application of Comput-8 in preparation of a product for relieving or treating retina degeneration induced by blue light damage. It is found for the first time that Compond-8 has a protection effect on retina rod cells and cone cells induced by blue light damage, the cilia length, density and membrane disc thickness of the cone cells and the rod cells can be increased, the thickness of a retina outer nuclear layer can be increased, photoreceptor cell damage caused by blue light exposure can be remarkably improved, and the photoreceptor cell damage can be remarkably reduced. The retina degeneration caused by blue light injury can be relieved or treated, and a new thought and means are provided for treatment of the retina degeneration induced by the blue light injury.

The invention discloses a phloretin derivative and application thereof in preparation of a medicine for treating diabetes, relates to the technical field of medicines, and in particular relates to a compound as shown in a formula (1) and alpha-glucosidase inhibitory activity of the compound. Pharmacological experiment results show that the compound shown in the formula (1) has extremely high alpha-glucosidase inhibitory activity, so that the generation of glucose is inhibited, and the pharmacological action of resisting diabetes mellitus is exerted through the action mechanism.

The invention relates to the technical field of medicines, and particularly discloses a compound antihypertensive pharmaceutical composition. The pharmaceutical composition provided by the invention selects sacubitril valsartan sodium and indapamide as active ingredients, and within a prescription dosage range limited by the application, the two medicines can fully realize an antihypertensive effect through a synergistic effect, and the renal function of a patient is effectively improved. Through cooperation of the two components, the hypertension symptom of a patient can be effectively controlled, the adverse reaction is not obvious, and the compliance of the patient can be improved by adopting the compound preparation, so that the control on the blood pressure of the patient is enhanced.

The invention belongs to the technical field of medicines, and particularly relates to a benzothiophene compound as well as a pharmaceutical composition, a pharmaceutical preparation and application thereof. The benzothiophene compound has a structure as shown in a formula (I), has a very strong excitation effect on an STING-mediated interferon signal channel, can be used as a small-molecule STING agonist, and is used for clinical treatment (especially immunotherapy) of tumors or infectious diseases. # imgabs0 #

The present invention provides an application of a thorn sugar neutral polysaccharide in preparing a drug for preventing and / or treating ulcerative colitis, and belongs to the field of medical technology. Animal experimental results show that after the thorn sugar neutral polysaccharide is used in a mouse model of ulcerative colitis, the phenomenon of colon shortening can be alleviated, the production of harmful bacteria can be inhibited, the abundance of Helicobacter genus can be reduced, the number of beneficial bacteria can be increased, and the abundance of Lactobacillus genus, Bacteroides genus and Oscillatory Spirochete genus can be increased. Therefore, the thorn sugar neutral polysaccharide of the present invention can be used as a drug for preparing a drug for preventing or treating ulcerative colitis.

The invention relates to the technical field of medicines. The invention provides sapropterin hydrochloride powder and a preparation method thereof. The sapropterin hydrochloride powder comprises the following components in percentage by mass: 15%-30% of sapropterin hydrochloride, 50%-60% of a filler, 8%-18% of a cosolvent, 3%-6% of a lubricant, 1%-3% of a flavoring agent and 0.1%-1% of an antioxidant. The sapropterin hydrochloride powder prepared by adopting the technical scheme has the characteristics of good solubility, high stability, high bioavailability and convenience in taking.

The present application is applicable to the field of medical technology, and provides a pharmaceutical composition for preventing and treating diabetic vascular calcification and a preparation method thereof, wherein the pharmaceutical composition comprises the following raw materials by mass: 15-25 parts of salvia miltiorrhiza, 9-12 parts of coptis chinensis, 9-12 parts of knotweed, 9-15 parts of rhodiola rosea and 9-12 parts of ebony. The present application uses a pharmaceutical composition prepared by compounding salvia miltiorrhiza, coptis chinensis, knotweed, rhodiola rosea and ebony in proportion, which can prevent and treat diabetic vascular calcification; in addition, it can also effectively improve blood sugar metabolism, and has the function of reducing aortic calcium salt deposition and improving aortic pathological morphology.

The invention relates to the technical field of medicines, in particular to application of an active ingredient xanthohumol (XAN) derived from a traditional Chinese medicine humulus lupulus in preparation of medicines for reducing uric acid and resisting gout, and the xanthohumol (XAN) can be prepared into various oral preparations, injection preparations and external preparations with the assistance of pharmaceutically acceptable auxiliary materials and has good development and application prospects. The inventor finds that the xanthohumol has relatively strong effects of reducing blood uric acid, resisting inflammation, resisting bone damage and the like, and the mechanism of the effect of reducing the blood uric acid is that the activity of xanthine oxidase is inhibited so as to reduce the generation of uric acid, and the renal function of an organism is improved so as to enhance uric acid excretion; according to the anti-inflammatory effect, the inflammatory reaction is relieved mainly by down-regulating the levels of inflammatory factors such as IL-1beta, IL-6, TNF alpha and PEG2; the mechanism for resisting gout bone damage is realized through the fact that RANKL / OPG / RANK signal pathway participates in bone metabolism regulation.

This invention relates to the field of pharmaceutical technology, specifically to a substituted pyridotriazole compound, its preparation method, and its uses. This specification discloses a substituted pyridotriazole compound that inhibits RIPK1 and / or MLK, as well as its pharmaceutically acceptable salts, stereoisomers, solvent compounds, or prodrugs. The compound is shown in formula (I), where the definitions of each group are detailed in the specification. Furthermore, this invention also discloses pharmaceutical compositions comprising this compound and their use in the preparation of medicaments for treating RIPK1-related diseases or conditions.

The invention belongs to the technical field of medicines, and provides a refining method and application of high-purity epalrestat. The refining method of the high-purity epalrestat comprises the following steps: adding an epalrestat crude product into a mixed solvent of a solvent A and a solvent B, stirring and dissolving in a dark place at 60-80 DEG C, stirring and refluxing for 0.5-2 hours, then carrying out gradient cooling to 20-40 DEG C, carrying out heat preservation and stirring crystallization for a certain time, carrying out suction filtration, and drying at 80 DEG C to obtain the epalrestat refined product. The mass volume ratio of the epalrestat crude product to the mixed solvent is (1: 8)-(1: 12). The solvent A is a good solvent, the solvent B is a poor solvent, and the volume ratio of the solvent A to the solvent B is 3: 1.5-3: 10. The yield of the epalrestat refined product prepared by the method is greater than 80%, and the purity is not less than 99.9%. Isomer impurities A and B are not detected, the content of an isomer impurity C is less than 0.05%, and the content of other maximum single impurities is not more than 0.06%.

The invention relates to an algin sulfate (PMGS) patch as well as a preparation method and application thereof, and belongs to the technical field of medicines. According to the application, the fucoidan polysaccharide sulfate (PMGS) is used as a main raw material of the microneedle for the first time, the needle tip is completely composed of PMGS, the PMGS plays a role in medicine and adjuvant integration, on one hand, the PMGS is used as a needle tip matrix to provide enough mechanical strength to pierce warts and surrounding skin and is more suitable for related warts with obvious skin thickening, and on the other hand, the PMGS is diffused and released at the position where viruses are located, so that the effect of preventing and treating warts is achieved. The skin wart treatment effect is achieved by preventing virus from entering and enhancing skin immunity, compared with a previous authorized patent scheme, the problems that PMGS as macromolecular polysaccharide enters the skin and is insufficient in absorption are solved in a microneedle mode, PMGS can be directly delivered to basal layer cells where HPV is located, and fixed-point drug delivery is achieved.

The utility model discloses a tablet detecting and sorting device, and relates to the technical field of pharmacy. Comprising a feeding mechanism used for providing tablets, a separating mechanism used for outputting the tablets one by one, a conveying mechanism used for conveying the tablets in a matrix mode, a machining head used for machining the tablets, a camera used for detecting the appearances of the tablets, a defective product box used for collecting the tablets with the unqualified appearances, and a supplementing mechanism used for supplementing the qualified tablets. And the negative pressure discharging belt is used for matrix type discharging. According to the utility model, manual operation is not needed, high-efficiency and high-accuracy detection and sorting can be carried out on tablets in a full-automatic manner, the possibility that inferior-quality products are mixed into qualified products is greatly reduced, the qualified products can be conveyed to the downstream in a tidy and matrix arrangement manner, the qualified products can be directly connected with various packaging devices for use, and the applicability is stronger.

The invention relates to the technical field of medicine, in particular to application of beta-hydroxybutyric acid in preparation of medicine for preventing and / or treating osteoporosis, the osteoporosis comprises postmenopausal osteoporosis and diabetic osteoporosis due to estrogen deficiency, the administration concentration of the beta-hydroxybutyric acid is 150mM, and the administration concentration of the beta-hydroxybutyric acid is 10mM. According to the application of the beta-hydroxybutyric acid in preparing the medicine for inhibiting osteoclast differentiation or osteoclast formation, the beta-hydroxybutyric acid inhibits osteoclast precursor cells from being differentiated into osteoclasts, and the administration concentration of the beta-hydroxybutyric acid is 10 mM; the invention proves that the beta-hydroxybutyric acid improves bone microstructures of OVX mice and db / db mice, inhibits osteoclast differentiation and reduces bone resorption, and provides a new target for prevention and treatment of osteoporosis.

The invention relates to the technical field of medicines, and provides a synergetic nano chemotherapy preparation for treating pancreatic cancer and a preparation method of the synergetic nano chemotherapy preparation. According to the synergistic nano chemotherapy preparation, an RGD peptide modified lipid-mesoporous silica nano delivery system is used for simultaneously encapsulating a ferroptosis inducer Erastatin and a chemotherapy drug gemcitabine hydrochloride hcGEM. The nano synergistic treatment system not only can actively deliver the drug to the pancreatic tumor tissue with high expression of the integrin receptor in a targeted manner through the surface-modified RGD peptide, but also can realize drug synergistic treatment, and improves the killing effect of the drug on pancreatic cancer cells while reducing the toxic and side effects.

The invention discloses application of Eucommia lignan in preparation of drugs for preventing and treating sepsis in the technical field of medicines. According to the scheme, the effects of the eucommia ulmoides lignan on the aspects of relieving sepsis inflammatory response, regulating cell phenotype and related protein gene expression, relieving neuron damage and the like are fully verified from the cell and animal levels, and the application value of the eucommia ulmoides lignan in preparation of the medicine for preventing and treating sepsis is proved.

The invention discloses application of an Aurora-A kinase inhibitor combined with dorafenib in preparation of a medicine for treating hepatocellular carcinoma, and relates to the technical field of medicines. The Aurora-A kinase inhibitor is Alisertib, and the Aurora-A kinase inhibitor is Alisertib. The dorafenib pharmaceutical composition has the beneficial effects that the dorafenib and the Aurora-A inhibitor Alisertib are jointly applied to form the pharmaceutical composition, so that a remarkable synergistic anti-tumor effect is achieved; to a certain extent, the problem of drug resistance during single-drug treatment is effectively solved; moreover, the pharmaceutical composition can achieve a remarkable anti-tumor effect at a relatively low dosage, and the dosage demand when a single drug is used is reduced, so that the potential toxic and side effects are reduced, and the pharmaceutical composition has a good clinical application prospect.

The invention belongs to the technical field of biochemical pharmacy, and particularly relates to a bezoar intermediate and a preparation method of bezoar. The preparation method comprises the following steps: mixing preparation raw materials and biochemical reaction liquid to obtain a mixed raw material solution; the preparation raw materials comprise bilirubin, organic active raw materials and vitamins, the biochemical reaction liquid is sterile purified water, and the bilirubin comprises bilirubin or biliverdin; and reacting the mixed raw material solution to obtain the bezoar intermediate. The content of combined bilirubin in the bezoar intermediate prepared by the preparation method provided by the invention is 75%-85%, the content of combined biliverdin is 73%-83%, and the yield is 83%-87%. According to the method, the poisoning and destroying effects of mycotoxin on the content, the yield, the biological activity and the oxidation resistance of the bezoar intermediate are effectively eliminated. The content, the yield, the oxidation resistance and the biological activity of the bezoar intermediate are greatly improved, the performance is stable, and the quality of bezoar is ensured.